VALNValneva SE

Nasdaq valneva.com


$ 6.07 $ -0.22 (-3.47 %)    

Tuesday, 17-Sep-2024 15:59:02 EDT
QQQ $ 474.02 $ -0.54 (-0.11 %)
DIA $ 417.38 $ 0.48 (0.12 %)
SPY $ 563.54 $ -0.32 (-0.06 %)
TLT $ 100.36 $ 0.04 (0.04 %)
GLD $ 237.90 $ -0.29 (-0.12 %)
$ 6.07
-- x --
-- x --
-- - --
$ 6.04 - $ 14.49
65,433
na
-4
$ 2.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 valneva-expands-chikungunya-vaccine-access-submits-label-extensions-for-ixchiq-to-ema-and-health-canada

  To potentially include adolescents and antibody persistence up to two years. In addition to ramping up sales, Valneva is foc...

 pfizer-and-valneva-partnered-lyme-disease-vaccine-shows-effectiveness-as-booster-shot-in-mid-stage-study

Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune re...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

Core News & Articles

The immune response and safety profile of VLA15 one month after receiving the second booster dose were similar to those reporte...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 valneva-reaffirmed-its-2024-guidance-expects-total-revenues-of-170m-190m-and-rd-investments-between-60m-75m

Full-year 2024 Financial Guidance Confirmed Expected total revenues between €170 million and €190 million, including €160 mi...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 valneva-and-limmatech-forge-strategic-partnership-to-fast-track-development-of-leading-tetravalent-shigella-vaccine

Valneva obtains exclusive worldwide license for LimmaTech's S4V Shigella vaccine candidate and adds an attractive Phase 2...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 cepi-and-eu-grant-valneva-413m-to-enhance-global-reach-of-chikungunya-vaccine-ixchiq

Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ® Fun...

 pfizervalnevas-vaccine-study-for-tick-borne-infection-completes-primary-vaccination-series-plans-approval-in-2026

Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease...

Core News & Articles

Participants completed primary vaccination series (3 doses) with VLA15 Primary vaccination series to be followed by a booster a...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION